ACRO Biomedical

Executive Summary

ACRO Biomedical Co., Ltd. is a Taiwan-based medtech company specializing in collagen-based medical devices and regenerative medicine products, leveraging proprietary supercritical CO₂ (scCO₂) decellularization technology. The company's portfolio spans wound care, orthopedics, dentistry, ophthalmology, and dermatology, offering sterile, low-allergy collagen scaffolds for tissue repair and regeneration. Founded in 2014, ACRO has achieved commercial-stage operations and focuses on addressing unmet needs in tissue regeneration with products that aim to reduce immunogenicity and enhance healing outcomes. As a private company, ACRO benefits from Taiwan's strong medtech ecosystem and is positioned to capture growth in the Asia-Pacific regenerative medicine market. Its scCO₂ technology differentiates it by enabling gentle removal of cellular components while preserving the native extracellular matrix structure, potentially leading to superior clinical performance. ACRO's clinical and regulatory progress, along with potential strategic partnerships, could drive near-term value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for a wound care collagen scaffold60% success
• Q4 2025Strategic distribution partnership for Southeast Asian markets70% success
• Q1 2026Publication of clinical data for orthopedic collagen membrane50% success